Biotechs looking so good the pharmas have designs on them

The biotech sector offers a great buying opportunity for investors right now as they are cheap and fundamentals are excellent. Furthermore, there may be a major catalyst in the form of M&A activity, with large-cap pharmaceuticals potentially buying biotech companies. Ever since the early 1980s research and development productivity in large-cap pharmas has declined. Many of today’s blockbuster products were discovered about this time and have fixed patent lines that are due to expire in the coming years. When this happens, generic companies can launch their copies of the product onc...